ライフサイエンスコーパス: rubella vaccine

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 f vaccination with >2 doses of measles-mumps-rubella vaccine.

2 ic conditions in women receiving the RA 27/3 rubella vaccine.

3 ults, we summarize the safety of introducing rubella vaccine across demographic and coverage contexts

4 accine to the incorporation of measles-mumps-rubella vaccine administered in the routine program.

5 mine seroconversion rates with measles-mumps-rubella vaccine administered to children at 9, 12, or 15

6 f seizures compared with measles, mumps, and rubella vaccine administered with or without varicella v

7 cted and geocoded tweets about measles-mumps-rubella vaccine and classified their sentiment using mac

8 at the same time they receive measles-mumps-rubella vaccine and may be given at the same time as oth

9 One dose of measles-rubella vaccine at age 15 months closed the remaining me

10 measles vaccine at age 9 months and measles-rubella vaccine at age 15 months.

11 Immune responses to current rubella vaccines demonstrate significant inter-individua

12 ncreased risk was associated with receipt of rubella vaccine for any outcome except for prevalence of

13 22) genes were significantly associated with rubella vaccine humoral immunity.

14 rease the body of knowledge on the safety of rubella vaccine if an unknowingly pregnant woman is vacc

15 and adolescents aged 1-19 years with measles-rubella vaccine in support of achieving the Region of th

16 ates due to concerns about the measles-mumps-rubella vaccine in the UK, and increasing numbers of cas

17 a causal relationship between currently used rubella vaccine in the US and some chronic arthropathy w

18 1 alleles were significantly associated with rubella vaccine-induced antibodies.

19 ammatory genes that may assist in explaining rubella vaccine-induced immune response variations.

20 etic polymorphisms play an important role in rubella vaccine-induced immunity.

21 immunogenetic understanding of mechanisms of rubella vaccine-induced immunity.

22 provide guidance on the safe introduction of rubella vaccine into countries in the face of substantia

23 s that countries considering introduction of rubella vaccine into their immunisation programme assess

24 a vaccine soon after the measles, mumps, and rubella vaccine (<28 days), and in children who received

25 Measles, mumps, and rubella vaccine (MMR) or immune globulin (IG) are routin

26 have received a second dose of measles-mumps-rubella vaccine (MMR2) at kindergarten entry.

27 have received a second dose of measles-mumps-rubella vaccine (MMR2) at kindergarten entry.

28 A were offered a third dose of measles-mumps-rubella vaccine (MMR3), and serum specimens were obtaine

29 ity of concomitant administration of measles-rubella vaccine (MR) and a third dose of human rotavirus

30 high coverage(>95%) with 2 doses of measles-rubella vaccine needs to be maintained, measles-rubella

31 No association between measles/mumps/rubella vaccine or thimerosal-containing pertussis vacci

32 In 2000, the first World Health Organization rubella vaccine position paper was published to guide in

33 Use of combined measles-rubella vaccines provides an opportunity to eliminate ru

34 regnancy is a contraindication of receipt of rubella vaccine (RCV).

35 exposed to the live-attenuated measles-mumps-rubella vaccine regardless of route of administration.

36 of risk of CRS associated with administering rubella vaccine shortly before or during pregnancy.

37 nts who were vaccinated (measles, mumps, and rubella vaccine/tick-borne encephalitis vaccine/BCG vacc

38 ter inactivated poliovirus and measles-mumps-rubella vaccines to patients younger than 7 years than t

39 Estimated national coverage with measles-rubella vaccine was 79.2% (95% confidence interval, 77.6

40 Measles-rubella vaccine was introduced into the country's routin

41 spective immunogenicity trial of measles and rubella vaccines was conducted in Oman.

42 negative adults immunized with measles-mumps-rubella vaccine were studied.

43 fied, additional mass campaigns with measles-rubella vaccine will be necessary.

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。